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OBJECTIVES The purpose of this study was to investigate the efficacy and safety of amiodarone and
propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized,
placebo-controlled study.
BACKGROUND The effectiveness of amiodarone and propafenone in the treatment of patients with chronic
atrial fibrillation has not been adequately studied.
METHODS One hundred one patients (48 men, mean age 64 6 9 years) with atrial fibrillation lasting .3
weeks participated in the study. Thirty-four patients received amiodarone (300 mg intrave-
nously over 1 h, followed by 20 mg/kg over the next 24 h plus 600 mg orally, in three doses,
for 1 week, then 400 mg/day orally, for three weeks), 32 received propafenone (2 mg/kg
intravenously over 15 min, followed by 10 mg/kg over 24 h and then 450 mg/day orally, for
one month) and the remaining 35 served as control subjects. All patients received digoxin and
anticoagulant treatment as indicated (International Normalized Ratio 2 to 3).
RESULTS Conversion to sinus rhythm was achieved in 16 (47.05%) patients who received amiodarone,
in 13 (40.62%) who received propafenone and in none of the control subjects (p , 0.001 for
both groups vs. control subjects). Those who converted had smaller atria than those who did
not and atrial fibrillation of shorter duration in both the amiodarone and propafenone groups.
Treatment was discontinued in one patient of the propafenone group because of significant
QRS widening.
CONCLUSIONS Amiodarone and propafenone appear to be safe and equally effective in the termination of
chronic atrial fibrillation. Left atrial diameter and arrhythmia duration are independent
predictors of conversion. (J Am Coll Cardiol 1999;33:966–71) © 1999 by the American
College of Cardiology
Previous studies suggest that both amiodarone and
propafenone are highly effective in restoring sinus rhythm in
patients with recent onset atrial fibrillation (1–8). However,
their effect on patients with long-lasting atrial fibrillation, a
condition under which chemical agents exhibit their lowest
conversion rate, has not been adequately studied.
The purpose of the present randomized, comparative,
placebo-controlled study was to assess the efficacy and safety
of both amiodarone and propafenone in restoring sinus
rhythm in patients with chronic atrial fibrillation (lasting
.3 weeks).
METHODS
Patients. From a total of 115 consecutive patients with
chronic atrial fibrillation who came to the emergency
department or were treated in our clinic, 101 (48 men, 53
women, mean age 64 6 9 years) were selected for inclusion
in the study. Patients with recent myocardial infarction (one
patient), heart surgery within the last six months (one
patient), acute pericarditis (two patients), severe uncon-
trolled heart failure (ejection fraction ,30%) or cardiogenic
shock (four patients), significant chronic obstructive pulmo-
nary disease (three patients) or thyroid disease (three pa-
tients) were excluded. Other exclusion criteria were unstable
angina, acute myocarditis, pulmonary embolism, pneumo-
nia, liver or kidney failure, electrolyte disturbances, preg-
nancy or lactation, age ,18 years, sick sinus syndrome, a
history of second- or third-degree atrioventricular block or
the taking of any other antiarrhythmic drug apart from
digoxin within a period less than five half-lives of the drug
in question before the study.
Study protocol. The study was approved by the hospital’s
Ethics Committee. After informed consent was obtained,
patients were randomized to receive either amiodarone,
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propafenone or placebo. Patients randomized to amioda-
rone received 300 mg intravenously for 1 h and then
20 mg/kg over 24 h. At the same time, they were given
600 mg per day in three doses, orally, for one week.
Thereafter they received 400 mg per day for 3 weeks.
Patients randomized to propafenone began with 2 mg/kg
intravenously over 15 min, followed by 10 mg/kg over 24 h
and then 450 mg/day, orally, for one month. Patients in the
placebo group received an identical amount of saline on the
first day, and then oral placebo for one month. Digoxin
(0.5 mg intravenously initially, followed by 0.25 mg at 2 h
and 0.25 mg every 6 h thereafter) was administered for 24 h
to all patients who had not previously received it. Subse-
quently, the digoxin dosage was adjusted to maintain
therapeutic serum concentrations in all patients. To prevent
thromboembolic episodes, all patients who were not already
taking anticoagulant medication were given acenocoumerol
(International Normalized Ratio 2 to 3) for .21 days before
cardioversion was attempted. This treatment was continued
for 21 days after successful cardioversion or indefinitely
when cardioversion was not achieved.
Monitoring and follow up. During the first 24 h (during
intravenous administration) all patients were kept in the
coronary care unit under continuous monitoring of the
electrocardiogram (ECG) and blood pressure. They were
then kept under observation in the cardiology department
for at least two days before being discharged. Patients were
evaluated in the clinic after the completion of one week of
treatment and then each week until one month. Before the
patients’ entry into the study, a full history was taken and
the following examinations were carried out: physical as-
sessment, 12-lead ECG, 24-h ambulatory ECG, chest
roentgenogram and test of liver function. At each weekly
follow-up visit, physical examination, routine laboratory
tests, 12-lead ECG and rhythm strip were repeated. Tests
of thyroid function were performed before entry and at the
one-month visit. An echocardiographic examination was
performed in all patients within a period of 7 to 30 days
after they were entered into the study.
Definition of terms. Atrial fibrillation was considered
chronic when its duration was at least three weeks, with no
instances of sinus rhythm. For the precise determination of
the onset of atrial fibrillation we took into account the
electrocardiographically proven time of onset (for patients
treated in our clinic) or the clearly determined time of onset
of symptoms such as palpitations, dyspnea and chest con-
gestion (for those patients who came to the emergency
department). Repeated 12-lead ECG and 24-h Holter
recordings were used to document the chronic nature of the
arrhythmia before cardioversion.
Treatment was considered successful if conversion to
sinus rhythm was achieved within the study period. In
patients who did not convert to sinus rhythm, conversion
was attempted using other antiarrhythmic drugs or current
cardioversion.
Statistical analysis. Summary descriptive statistics are ex-
pressed as mean 6 SD. Patients in whom normal sinus rhythm
was restored by the end of the 1-month observation period
were censored. All patients had complete follow-up data.
Continuous variables were compared using the unmatched t
test and categorical data by the chi-square test or Fisher exact
test as appropriate. To assess whether the two drugs differed
significantly in their effect, time to normal sinus rhythm curves
were constructed using the Kaplan–Meier product limit esti-
mate method and compared using the log-rank test. Log-rank
comparisons of Kaplan–Meier curves were also used for a
univariate assessment of the prognostic value of potential risk
factors, such as age, gender, left atrial diameter, left ventricular
ejection fraction, baseline ventricular rate, underlying cardiac
disease and atrial fibrillation duration, measured at study entry.
For all comparisons a p value ,0.05 was the criterion for
significance.
RESULTS
Of the 101 patients who were enrolled, 34 were randomized
to amiodarone, 32 to propafenone and 35 to placebo. There
were no significant differences between the three groups
regarding age, gender, duration of atrial fibrillation, under-
lying cardiac disease, baseline ventricular rate, left atrial size
or left ventricular ejection fraction measured echocardio-
graphically (Table 1). Twelve patients (4 on amiodarone,
3 on propafenone and 5 on placebo) had had previous
Table 1. Characteristics of the Patients Studied
Patients’
Characteristics
Amiodarone
Group
Propafenone
Group
Placebo
Group
Number of patients 34 32 35
Gender
(male/female)
16/18 16/16 16/19
Age (yr) 64 6 9 64 6 10 63 6 9
Mean ventricular rate
(beats/min)
93 6 10 92 6 15 94 6 14
Systolic blood
pressure (mm Hg)
134 6 16 135 6 14 133 6 13
Underlying cardiac
disease (%)
14 (41.17) 13 (40.62) 15 (42.85)
AF duration (days) 162 6 95 162 6 100 163 6 100
Left atrial diameter
(mm)
46.89 6 8.15 47.63 6 5.68 47.97 6 5.90
LVEF (%) 50 6 8 51 6 6 50 6 8
No significant differences were found between the three groups.
AF 5 atrial fibrillation; LVEF 5 left ventricular ejection fraction.
Abbreviations and Acronyms
ECG 5 electrocardiogram
NS 5 non-significant
SD 5 standard deviation
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successful cardioversion (seven electrical). Seven of these 12
were under medication for the maintenance of sinus rhythm
(four on sotalol, two on disopyramide, one on quinidine).
These medications were discontinued five half-lives before
the time of the patients’ entry to the study.
Conversion to sinus rhythm. Three of the 32 (9.3%)
patients receiving propafenone and none of those given
amiodarone or placebo converted to sinus rhythm within the
first 24 h.
At two weeks, another 10 patients in the propafenone
group had converted, making 13 of the 32 in all (40.7%).
Eleven of the 34 (32.4%) in the amiodarone group and none
of the placebo group had converted. The first conversion in
the amiodarone group was on day 9.
By the end of the study period five more of the patients
receiving amiodarone had converted, making 16 in all
(47.05%). No other patients receiving propafenone and
none of those receiving placebo had converted to sinus
rhythm (p , 0.001 for amiodarone or propafenone vs.
placebo for the whole study period). In 17 patients (5 on
amiodarone, 3 on propafenone, 9 on placebo) beta-
adrenergic blocking agents were added to the treatment
regime to achieve better control of the heart rate. Of these
patients, 4 (3 on amiodarone, 1 on propafenone) converted.
The estimated mean time to conversion was 23 6 1.4
days in the amiodarone group and 20 6 2 days in the
propafenone group (p 5 NS). Figure 1 shows the cumula-
tive conversion progression to normal sinus rhythm in the
two treatment groups.
Predictors of conversion. Since none of the patients re-
ceiving placebo converted, we restricted our attention to the
other groups, to identify potential predictors of conversion.
As can be seen in Table 2, those who converted to sinus
rhythm after treatment with either amiodarone or
propafenone had atrial fibrillation of shorter duration and
smaller atria than those who did not. Gender, age, left
ventricular ejection fraction, underlying cardiac disease and
the baseline heart rate did not appear to have any significant
relationship with conversion in any group.
To examine the role of left atrial size and atrial fibrillation
duration in more detail, we dichotomized these two predic-
tors at the statistical median and computed the conversion
rates for both drugs (Table 3). Patients with left atrial size
#48 mm or atrial fibrillation duration ,3 months had very
high monthly conversion rates with either amiodarone or
propafenone. In contrast, in patients with left atrial size
Figure 1. The cumulative conversion progression to normal sinus
rhythm (NSR) in the amiodarone and propafenone groups. It is
clear that propafenone starts to convert earlier than amiodarone;
none of our patients receiving this drug converted after more than
15 days. In contrast, amiodarone, while having a delayed onset of
action (.9 days), continued to cardiovert at a steady rate.
Table 2. Predictors of Conversion by Drug Treatment (Univariate Assessment)
Drug
Potential Risk
Factors Conversion
No
Conversion
p
Value
Amiodarone Gender (male/female) 8/8 8/10 NS
Age (yr) 66 6 8 63 6 9 NS
Mean ventricular rate (beats/min) 94 6 11 92 6 8 NS
Systolic blood pressure (mm Hg) 135 6 16 133 6 14 NS
Underlying cardiac disease (%) 6 (42.85) 8 (57.15) NS
AF duration (days) 108 6 44 210 6 103 0.001
Left atrial diameter (mm) 41.04 6 6.67 52.08 6 5.37 , 0.001
LVEF (%) 52.81 6 7.06 47.77 6 7.90 NS
Propafenone Gender (male/female) 6/7 10/9 NS
Age (yr) 62 6 13 65 6 8 NS
Mean ventricular rate (beats/min) 90 6 20 92 6 19 NS
Systolic blood pressure (mm Hg) 137 6 15 132 6 17 NS
Underlying cardiac disease (%) 6 (46.15) 7 (53.85) NS
AF duration (days) 99 6 54 206 6 102 0.001
Left atrial diameter (mm) 42.93 6 4.73 50.84 6 3.70 , 0.001
LVEF (%) 52 6 6 50 6 5 NS
Abbreviations as in Table 1.
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.48 mm or atrial fibrillation duration .3 months the
conversion rates for both agents were dramatically lower.
Furthermore, as Figure 2 clearly shows, patients with left
atrial size #48 mm or atrial fibrillation duration ,3 months
had a greater likelihood of converting sooner, rather than
later.
A multivariate stepwise proportional hazards Cox regres-
sion model revealed that left atrial size and atrial fibrillation
duration were the only independently significant factors
affecting time to conversion, (chi-square 5 28.9, beta 5
20.1 6 0.02, p , 0.0001, and chi-square 5 8.4, beta 5
20.008 6 0.031, p , 0.003, respectively). More precisely,
the model implies that a 5-mm increase in left atrial size
results in a 42% reduction in the conversion rate; every
month of atrial fibrillation duration reduces the conversion
rate by 22%.
Adverse effects. Treatment was discontinued in only one
patient (propafenone group) because of significant QRS
widening (from 0.10 to 0.16 s). No other adverse effects
necessitating drug discontinuation occurred.
There were no proarrhythmic effects, defined as the new
onset of sustained ventricular tachycardia, ventricular fibril-
lation or torsades de pointes, either in patients who con-
verted to sinus rhythm or in those who remained in atrial
fibrillation.
No side effects were observed in the placebo group.
DISCUSSION
Propafenone and amiodarone are considered to be among
the most promising antiarrhythmic agents (1–8). Propa-
fenone markedly slows conduction in the atrial myocardium
(class lc antiarrhythmic drug), whereas amiodarone mainly
Table 3. Conversion Rate (%) of Significant Predictors
Dichotomized at the Statistical Median
Significant
Risk Markers
Treatment
Amiodarone Propafenone
Left atrial diameter #48 mm 88.5 70.6
.48 mm 11.11 6.7
AF duration #3 months 68.75 60
.3 months 27.8 23.53
AF 5 atrial fibrillation.
Figure 2. The cumulative conversion progression to normal sinus rhythm (NSR) in the amiodarone and propafenone groups in relation
to the significant predictors. It can be seen that patients with left atrial (LA) size #48 mm or duration of atrial fibrillation (AF) ,3 months
have a greater likelihood of converting within a shorter time. Furthermore, patients with left atrial size .48 mm or arrhythmia lasting .3
months start to convert late with both drugs.
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prolongs the effective refractory period of atrial myocardial
cells (class III drug) (6,9). On the basis of the leading theory
of atrial reentry and atrial fibrillation, drugs that have these
properties should be potent antifibrillatory agents (4,9).
Although the effectiveness of these two drugs in the
cardioversion of recent onset atrial fibrillation has been well
documented, their effectiveness in cases of chronic atrial
fibrillation has not been studied adequately. Existing studies
of amiodarone or propafenone are few and include small
numbers of patients. Furthermore, most of them did not use
a placebo control group, and so the real value of their
findings is limited (1–4,6–8,10). For this reason, our study
was structured in such a way as to enable us both to evaluate
the real efficacy and safety of the two drugs tested for the
conversion of chronic atrial fibrillation and to make a
comparison between them.
Efficacy of the drugs. Our findings indicate that both
amiodarone and propafenone could be used for the conver-
sion of chronic atrial fibrillation to sinus rhythm. However,
factors such as the duration of chronic atrial fibrillation and
the size of the left atrium must be taken into account.
Patients with a small left atrium and/or relatively short
lasting atrial fibrillation show the highest conversion rates
and therefore reap the most benefit from treatment with
both drugs. The larger the left atrium and the longer the
duration of the atrial fibrillation, the lower the efficacy of
both drugs, with the result that patients with a very large left
atrium or long-lasting atrial fibrillation have a low conver-
sion rate. However, the fact that these patients, according to
our results, do not convert spontaneously, shows that both
agents could be of some benefit even in such cases.
According to our findings, both agents are equally effec-
tive in restoring sinus rhythm in patients with chronic atrial
fibrillation, even though they have different mechanisms of
action. However, if we examine the results more carefully
we see that propafenone starts to convert earlier; none of our
patients receiving this drug converted after more than 15
days. In contrast, amiodarone, while relatively slow in terms
of its first successful conversion (.9 days), continued to
cardiovert at a steady rate until the end of the observation
period. It is therefore possible that the slight superiority of
amiodarone observed at 1 month (47% vs. 41%) could
become significant with more months of treatment, assum-
ing of course that amiodarone would continue to cardiovert
at the same rate. The fact that amiodarone is known to have
a relatively slow onset of activity, with its full action as a
class III agent appearing after at least 1 month, explains its
delayed effectiveness in cardioversion and supports our
suggestion (1–3,9–11).
Time to conversion. The size of the left atrium and the
duration of chronic atrial fibrillation affect not only the
likelihood of conversion to sinus rhythm but also when this
will happen. The larger the left atrium and the longer the
duration of atrial fibrillation, the later the conversion is
likely to occur, under treatment with either amiodarone or
propafenone. It is indicative that all of our patients who had
a large left atrium (.48 mm) or long-lasting atrial fibrilla-
tion (.3 months) began to convert after more than 6 days,
regardless of treatment (Fig. 2). This probably has to do
with the fact that both agents, amiodarone especially, need
a long time to achieve their full efficacy, which is clearly
needed in difficult cases such as these. Potential mechanisms
for this are, first, the slow accumulation of both agents in
the myocardium, which has been observed in previous studies,
and second, the fact that both propafenone and amiodarone
metabolize into substances (5-hydroxypropafenone and des-
ethylamiodarone, respectively) that are able to exert anti-
arrhythmic effects and the levels of which increase gradually
during long periods of administration (5,6,10–14).
Intravenous and oral administration. Both drugs were
administered in a combination of intravenous and oral
doses. This approach was designed to assess the role of the
long-term oral administration of the two agents in the
conversion of chronic atrial fibrillation in cases resistant to
the short-term treatment, and not to make a direct com-
parison of the two modes of treatment. There are already
many studies, especially in the case of propafenone, which
have compared intravenous with oral administration and
have come to the conclusion that there are no significant
differences as regards effectiveness (1–6).
Previous studies. Previous studies that investigated the
effect of chemical cardioversion on chronic atrial fibrillation
reported lower conversion rates, both with amiodarone or
propafenone and with other drugs (1–4,6,7,10,15–21). Our
good results probably have to do with the long time of
administration of the two agents in our study. This hypoth-
esis is reinforced by the findings of Kerin et al. (18), who
observed for amiodarone that the longer the duration of
treatment, the higher the conversion rate.
Regarding the roles of atrial fibrillation duration and left
atrial size in the conversion of atrial fibrillation, our results
are not surprising. Most controlled trials of antiarrhythmic
agents agree that the size of the left atrium and the duration
of the arrhythmia are significant factors affecting the likeli-
hood of the conversion of atrial fibrillation to sinus rhythm
(1–4,22). However, the observation that they also affect the
time needed for conversion is new.
Safety. Our results show that both agents are quite safe in
the restoration of sinus rhythm. Only in one patient
receiving propafenone did treatment have to be discontin-
ued because of QRS widening. However, previous studies
have reported significant side effects for both drugs. More
specifically, amiodarone has been implicated in many car-
diac and noncardiac side effects. It has been proved that the
majority of the side effects of amiodarone are dose related;
thus, the absence of side effects in our patients was probably
due to the relatively short time of administration (1–4,23).
As regards propafenone, previous studies have reported a
significant proarrhythmic effect, especially in patients with
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underlying cardiac disease. The fact that such patients were
excluded from our study could explain our findings with
respect to the safety of propafenone (1–5).
Study limitations. In our study all patients received
digoxin. Digoxin was used in the control group to reduce
the high ventricular rate. We chose this drug because it did
not seem to affect the likelihood of conversion. Falk et al.
(24), in a small, randomized, controlled study, reported
similar conversion rates in a placebo group and a digoxin-
treated group. However, to exclude any potential benefit or
harm from digoxin in the conversion to sinus rhythm we
used it in all groups (amiodarone, propafenone and place-
bo).
Study implications. Although electrical cardioversion is
considered to be the treatment of choice in patients with
chronic atrial fibrillation, amiodarone and propafenone
could be used in cases where direct current cardioversion is
contraindicated, unavailable or refused. In particular, pa-
tients with a small left atrium and/or relatively short-
duration chronic atrial fibrillation have a high probability of
rapid conversion with both drugs; when the size of the left
atrium and the duration of the atrial fibrillation increase, so
the likelihood of conversion decreases.
The size of the left atrium and the duration of atrial
fibrillation also determine how long treatment must be
applied before conversion. The larger the left atrium and the
longer the duration of the arrhythmia, the longer the period
of treatment required for conversion. However, further
studies are needed to determine whether therapy over
periods longer than the one-month interval we studied
could lead to a higher overall success rate, especially in the
case of amiodarone.
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